The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial

BMC Pulmonary Medicine

Anne E Holland⁶  Alicia Martin²  Rebecca Ndongo⁴  Angela Burge⁶  Annemarie Southcott⁵  Nicole Goh³  Ian Glaspole³  Claire Boote²  Kathryn Barker²  Annemarie Lee⁶  Catherine Hill⁴  Christine F McDonald¹  Leona Dowman⁴ 

[1] The University of Melbourne, Melbourne, Australia;Department of Physiotherapy, Western Health, Melbourne, Australia;Allergy, Immunology & Respiratory Medicine Department, Alfred Health, Melbourne, Australia;Institute for Breathing and Sleep, Melbourne, Australia;Department of Respiratory & Sleep Disorders Medicine, Western Health, Melbourne, Australia;Department of Physiotherapy, Alfred Health, Melbourne, Australia

关键词: Rehabilitation;    Exercise;    Connective tissue diseases;    Hypersensitivity pneumonitis;    Sarcoidosis;    Asbestosis;    Idiopathic interstitial pneumonias;    Idiopathic pulmonary fibrosis;    Diffuse parenchymal lung diseases;    Interstitial lung diseases;   

Others  :  1131296
DOI  :  10.1186/1471-2466-13-8

 received in 2013-01-14, accepted in 2013-01-14,  发布年份 2013

【 摘 要 】

Background

Interstitial lung disease encompasses a diverse group of chronic lung conditions characterised by distressing dyspnoea, fatigue, reduced exercise tolerance and poor health-related quality of life. Exercise training is one of the few treatments to induce positive changes in exercise tolerance and symptoms, however there is marked variability in response. The aetiology and severity of interstitial lung disease may influence the response to treatment. The aims of this project are to establish the impact of exercise training across the range of disease severity and to identify whether there is an optimal time for patients with interstitial lung disease to receive exercise training.

Methods/Design

One hundred and sixteen participants with interstitial lung disease recruited from three tertiary institutions will be randomised to either an exercise training group (supervised exercise training twice weekly for eight weeks) or a usual care group (weekly telephone support). The 6-minute walk distance, peripheral muscle strength, health-related quality of life, dyspnoea, anxiety and depression will be measured by a blinded assessor at baseline, immediately following the intervention and at six months following the intervention. The primary outcome will be change in 6-minute walk distance following the intervention, with planned subgroup analyses for participants with idiopathic pulmonary fibrosis, dust-related interstitial lung disease and connective-tissue related interstitial lung disease. The effects of disease severity on outcomes will be evaluated using important markers of disease severity and survival, such as forced vital capacity, carbon monoxide transfer factor and pulmonary hypertension.

Discussion

This trial will provide certainty regarding the role of exercise training in interstitial lung disease and will identify at what time point within the disease process this treatment is most effective. The results from this study will inform and optimise the clinical management of people with interstitial lung disease.

Trial registration

Australian New Zealand Clinical Trials Registry ACTRN12611000416998

【 授权许可】

   
2013 Dowman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]American Thoracic Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002, 165:277-304.
• [2]Garvey C: Interstitial Lung Disease and Pulmonary Rehabilitation. J Cardiopulm Rehab Prevention 2010, 30:141-146.
• [3]Harris-Eze AO, Srihdar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD: Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. Am J Respir Crit Care Med 1996, 154:994-1001.
• [4]Hansen JE, Wasserman K: Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996, 109:1566-1576.
• [5]Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK: Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
• [6]Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, Arizono S: Quadriceps Weakness Is Related to Exercise Capacity in Idiopathic Pulmonary Fibrosis. Chest 2005, 127:2028-2033.
• [7]Holland AE: Exercise limitation in interstitial lung disease – mechanisms, significance and therapeutic options. Chron Respir Dis 2010, 7:101-111.
• [8]Chang JA, Randall Curtis J, Patrick DL, Raghu G: Assessment of Health-Related Quality of Life in patients with interstitial lung disease. Chest 1999, 116:1175-1182.
• [9]Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD: Pulmonary Hypertension in Patients with Interstitial Lung Diseases. Mayo Clin Proc 2007, 82:342-350.
• [10]Wells AU, Hirani N, on behalf of the British Thoracic Society Interstitial Lung Disease Guideline Group, Thoracic Society of Australia and New Zealand and the Irish Thoracic Society: Interstitial lung disease guideline. Thorax 2008, 63:v1-v58.
• [11]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ, on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: American Thoracic Society/ European Respiratory Society/Japanese Respiratory Society/ Latin American Thoracic Association Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 2011, 183:788-852.
• [12]Alfonso HS, Fritschi L, de Klerk NH, Olsen N, Sleith J, Musk AW: Effects of asbestos and smoking on the levels and rates of change of lung function in a crocidolite exposed cohort in Western Australia. Thorax 2004, 59:1052-1056.
• [13]De Lauretis A, Veeraraghavan S, Renzon E: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011, 8:53-82.
• [14]Lama VN, Martinez FJ: Resting and exercise physiology in interstital lung diseases. Clin Chest Med 2004, 25:435-453.
• [15]Glazer CS, Newman LS: Occupational interstitial lung disease. Clin Chest Med 2004, 25:467-478.
• [16]Swigris JJ, Brown KK, Make BJ, Wamboldt FS: Pulmonary rehabilitation in idiopathic pulmonary fibrosis: A call for continued investigation. Respir Med 2008, 102:1675-1680.
• [17]Holland AE, Hill CJ, Conron M, Munro P, McDonald CF: Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008, 63:549-55.
• [18]Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishimura K, Taniguchi H: Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008, 13:394-399.
• [19]Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR: Pulmonary Rehabilitation in Interstitial Lung Disease. Benefits and Predictors of Response. Chest 2009, 135:442-447.
• [20]Ferreira G, Feuerman M, Spiegler P: Results of an 8-week, outpatient pulmonary rehabilitation program on patients with and without chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2006, 26:54-60.
• [21]Jastrzebski D, Gumola A, Gawlik R, Kozielski J: Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol 2006, 57(Suppl):139-148.
• [22]Naji NA, Connor MC, Donnelly SC, Seamas C, McDonnell TJ: Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil 2006, 26:237-243.
• [23]Foster S, Thomas HM III: Pulmonary rehabilitation in lung disease other than chronic obstructive pulmonary disease. Am Rev Respir Dis 1990, 141:601-604.
• [24]Holland AE, Hill C: Physical training for interstitial lung disease. Cochrane Database Syst Rev 2008, 4:CD006322.
• [25]Behr J, Ryu JH: Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008, 31:1357-1367.
• [26]Strange C, Highland KB: Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005, 11:452-455.
• [27]Glaser S, Noga O, Koch B, Opitz CF, Schmid B, Temmesfeld B, Dorr M, Ewert R, Schaper C: Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med 2009, 103:317-324.
• [28]Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF: Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med 2012, 106:429-435.
• [29]Hunninghake GW, Zimmerman BM, Schwartz DA, King TE Jr, Lynch J, Hegele R, Waldron J, Colby T, Muller N, Lynch D, Galvin J, Gross B, Hogg J, Toews G, Helmers R, Cooper JAD Jr, Baughman R, Strange C, Millard M: Utility of a Lung Biopsy for the Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2001, 164:193-196.
• [30]Holland AE, Hill CJ, Conron M, Munro P, McDonald CF: Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009, 103:1430-1435.
• [31]Moher M, Schultz K, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001, 357:1191-1194.
• [32]Australian Lung Foundation and Australian Physiotherapy Association: Pulmonary rehabilitation toolkit. http://www.pulmonaryrehab.com.au webcite
• [33]Hill K, Jenkins SC, Cecins N, Phillipe DL, Hillman DR, Eastwood PR: Estimating Maximum work rate during incremental cycle ergometry testing from six minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2008, 89:1782-1787.
• [34]Borg G: Psychophysical bases of perceived exertion. Med Sci Sports Exer 1982, 14:377-381.
• [35]Kraemer WJ, Ratamess NA: Fundamentals of Resistance Training: Progression and Exercise Prescription. Med Sci Sports Exerc 2004, 36:674-688.
• [36]Storer TW: Exercise in chronic pulmonary disease: resistance exercise prescription. Med Sci Sports Exerc 2001, 33(Suppl 7):S680-S686.
• [37]Nici L, Donner CF, Wouters EF, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O’Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T, on behalf of the ATS/ERS Pulmonary Rehabilitation Writing Committee: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006, 173:1390-1413.
• [38]Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP: ACSM Position Stand. Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise. Med Sci Sports Exerc 2011, 43:1334-1359.
• [39]Sims J, Hill K, Hunt S, Haralambous B, Brown A, Engel L, Huang N, Kerse N, Ory M: National physical activity recommendations for older Australians: Discussion document. Australian Government Department of Health and Ageing, Canberra; 2006. http://www.mednwh.unimelb.edu.au/research/pdf_docs/discussion_doc.pdf webcite
• [40]American Thoracic Society: ATS Statement: Guidelines for the Six-Minute- Walk Test. Am J Respir Crit Care Med 2002, 166:111-117.
• [41]Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G: The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005, 25:96-103.
• [42]Leach RM, Davidson AC, Chinn S, Twort CHC, Cameron IR, Bateman NT: Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax 1992, 47:781-789.
• [43]Davidson AC, Leach R, George RJ, Geddes DM: Supplemental oxygen and exercise ability in chronic obstructive airways disease. Thorax 1988, 43:965-971.
• [44]Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJT, Demedts MG, Decramer M: Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005, 60:32-38.
• [45]Yorke J, Jones PW, Swigris JJ: Development and validity testing of an IPF-specific version of the St George’s Respiratory Questionnaire. Thorax 2010, 65:921-926.
• [46]Collard HR, Pantilat SZ: Dyspnea in interstitial lung disease. Curr Opin in Support and Palliat Care 2008, 2:100-104.
• [47]Kupferberg DH, Kaplan RM, Slymen DJ, Ries AL: Minimal Clinically Important Difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005, 25:370-377.
• [48]Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM: Validation of a New Dyspnea Measure. The UCSD Shortness of Breath Questionnaire. Chest 1998, 113:619-624.
• [49]Papiris SA, Daniil ZD, Malagari K, Kapotsis GE, Sotiropoulou C, Milic-Emili J, Roussos C: The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005, 99:755-761.
• [50]Mahler DA, Harver A, Rosiello R, Daubenspeck JA: Measurement of respiratory sensation in interstitial lung disease. Evaluation of clinical dyspnea ratings and magnitude scaling. Chest 1989, 96:767-771.
• [51]Tzanakis N, Lambiri I, Antoniou K, Siafakas N, Bouros D, Maria Samiou T: Evaluation of health related quality of life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Int Med 2005, 16:105-112.
• [52]Naji NA, Connor MC, Donnelly SC, McDonnell TJ: Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehab 2006, 26:237-243.
• [53]Deyo RA, Diehr P, Patrick DL: Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin trials 1991, 12:142s-158s.
• [54]Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Grinten van der C, Gustafsson C, Jensen R, Johnson D, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [55]Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin DJ: The Accuracy of the Clinical Diagnosis of New-Onset Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Disease. A Prospective Study. Chest 1999, 116:1168-1174.